Aldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Below 50 Day Moving Average – Here’s What Happened

Aldeyra Therapeutics, Inc (NASDAQ:ALDX)’s share price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $5.07 and traded as low as $4.83. Aldeyra Therapeutics shares last traded at $4.94, with a volume of 362,371 shares changing hands.

Aldeyra Therapeutics Stock Down 1.6 %

The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of $5.07 and a two-hundred day moving average price of $4.79.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.25). As a group, equities research analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. raised its stake in shares of Aldeyra Therapeutics by 163.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after purchasing an additional 295,864 shares in the last quarter. Federated Hermes Inc. bought a new stake in Aldeyra Therapeutics during the second quarter worth $1,758,000. International Assets Investment Management LLC lifted its stake in Aldeyra Therapeutics by 397.0% in the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock valued at $15,480,000 after acquiring an additional 229,487 shares during the last quarter. Perceptive Advisors LLC grew its position in shares of Aldeyra Therapeutics by 7.9% in the 2nd quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock valued at $30,703,000 after acquiring an additional 682,265 shares during the period. Finally, PFG Investments LLC acquired a new position in shares of Aldeyra Therapeutics during the 2nd quarter worth about $1,312,000. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.